The Critical Role of GALNTs‐Regulated O‐GalNAc Glycosylation in Cancer Malignancy
The FASEB Journal · 30.04.2026 · 40 (8)
DOI: 10.1096/fj.202504815r ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 21.04.2026. Verfasst von Jiahao Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: N-Acetylgalactosaminyltransferases, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the funding for scientific research and innovation team of the first affiliated hospital of zhengzhou university, the joint fund of henan provincial research and development program for science and technology.
Abstract (Originalsprache)
Aberrant mucin‐type O‐glycosylation, mediated by the Polypeptide N‐acetylgalactosaminyltransferase (GALNT) family of enzymes, is a defining feature of many cancers and has also been strongly linked to non‐neoplastic conditions, including developmental disorders and metabolic abnormalities. Mucin‐type O‐GalNAc glycosylation, a prevalent and highly specific form of post‐translational modification, is centrally involved in key processes underlying cancer progression, such as cell signaling, invasion, angiogenesis, and metastasis. It is intricately linked to a diverse array of human diseases, with a particular association with cancer. Ongoing research endeavors to elucidate the functional mechanisms by which GALNT enzymes regulate O‐GalNAc glycosylation, thereby enhancing our understanding of their pivotal roles in cancer biology. Although significant advances have been made in understanding their contributions to cancer initiation and progression, a comprehensive characterization of both the GALNT family and O‐GalNAc glycosylation in oncology remains lacking. This review aims to summarize the structure of the GALNT family and its regulatory roles in the initiation and elongation of O‐GalNAc glycans, providing an in‐depth exploration of the functions of GALNT‐mediated O‐GalNAc glycosylation in cancer. Ultimately, these insights will help uncover underlying oncogenic mechanisms and may offer new potential directions for the development of anticancer therapeutics and diagnostic biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
ORCID-Profile: Jiahao Liu, Sihan Wu, Ge Zhang, Jiehan Li, Yuhan Yin, Aman Uiiah, Sanfei Peng, Yang Fu
Förderung
- the funding for scientific research and innovation team of the first affiliated hospital of zhengzhou university
- the joint fund of henan provincial research and development program for science and technology
Zitieren
APA
Liu, J., Wu, S., Zhang, G., Li, J., Yin, Y., Uiiah, A., Peng, S., & Fu, Y. (2026). The Critical Role of GALNTs‐Regulated O‐GalNAc Glycosylation in Cancer Malignancy. The FASEB Journal, 40(8). https://doi.org/10.1096/fj.202504815r
Vancouver
Liu J, Wu S, Zhang G, Li J, Yin Y, Uiiah A, et al. The Critical Role of GALNTs‐Regulated O‐GalNAc Glycosylation in Cancer Malignancy. The FASEB Journal. 2026;40(8). doi:10.1096/fj.202504815r
BibTeX
@article{Liu2026,
author = {Liu, Jiahao and Wu, Sihan and Zhang, Ge and Li, Jiehan and Yin, Yuhan and Uiiah, Aman and Peng, Sanfei and Fu, Yang},
title = {The Critical Role of GALNTs‐Regulated O‐GalNAc Glycosylation in Cancer Malignancy},
journal = {The FASEB Journal},
year = {2026},
volume = {40},
number = {8},
doi = {10.1096/fj.202504815r}
}
EUVIMED